Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, announced on Thursday that the first patient has been dosed in a first-in-human global phase 1 study evaluating DS-1055.
The product is a GARP directed immuno-oncology therapy, for patients with advanced or metastatic solid tumours who have progressed on standard treatments including checkpoint inhibitors. GARP is highly expressed on activated regulatory T cells (Tregs) and contributes to their immunosuppressive activity. Research suggests that targeting GARP on Tregs may be a promising new immune intervention strategy. There are no GARP directed therapies currently approved for cancer treatment.
Arnaud Lesegretain, vice president, Global Oncology Development, Alpha Portfolio, Daiichi Sankyo, said, 'We are pleased to initiate clinical development to further evaluate the novel mechanism behind DS-1055, which was specifically designed to decrease the number of GARP expressing regulatory T cells and restore antitumor immune response. Evidence suggests that DS-1055 could serve as a new type of immune-based therapy for patients with various cancers, including those resistant or refractory to checkpoint inhibitors.'
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval